TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$460.1 Million


Follow-on Offering

Bookrunner, November 2022


Natera, Inc. (“Natera” or the “Company”) is a diagnostics company with proprietary molecular and bioinformatics technology that are deployed to change the management of disease worldwide. Natera began in the woman’s health space, developing and commercializing non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a wide range of genetic conditions, such as Down syndrome. Natera’s technology is now also being used in the oncology market, in which the Company is commercializing, among others, a personalized blood-based DNA test to detect molecular residual disease and monitor disease recurrence, as well as in the organ health market, with tests to assess organ transplant rejection.